Skip to main content
SpringerLink
Log in

Autoimmundermatosen

Systemische immunsuppressive Therapie in der Kinderdermatologie

  • Fortbildung
  • Published:
Pädiatrie Aims and scope

Autoimmundermatosen, die allein durch externe, topische Therapien meist nicht hinreichend einzudämmen sind, können oftmals durch systemische Immunsuppressiva erfolgreich therapiert werden. Dieser Artikel liefert einen kurzen Überblick kinderdermatologischer Erkrankungen, die den Einsatz systemischer Immunsuppressiva erforderlich machen können, und beschreibt die hierfür einsetzbaren Substanzen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1:
Abb. 2:
Abb. 3:
Abb. 4:
Tab. 1:

Literatur

  1. Arens A, Ott H. Systemische Ciclosporin-Therapie bei Kindern und Jugendlichen mit schwerem Atopischen Ekzem. Päd Allergo 2015; 18: 10–14.

    Google Scholar 

  2. de Jager ME, de Jong EM, van de Kerkhof PC et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010 Jun; 62: 1013–1030.

    Article  PubMed  Google Scholar 

  3. Midgley A, Watson L, Beresford MW. New insights into the pathogenesis and management of lupus in children. Arch Dis Child 2014 Jun; 99: 563–567.

    Article  CAS  PubMed  Google Scholar 

  4. Weibel L, Sampaio MC, Visentin MT et al. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol 2006 Nov; 155: 1013–1020.

    Article  CAS  PubMed  Google Scholar 

  5. Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 2011 Nov; 65: 925–941.

    Article  CAS  PubMed  Google Scholar 

  6. Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 2009 Oct; 23: 665–678.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Trnka P. Henoch-Schonlein purpura in children. J Paediatr Child Health 2013 Dec; 49: 995–1003.

    Article  PubMed  Google Scholar 

  8. Sansaricq F, Stein SL, Petronic-Rosic V. Autoimmune bullous diseases in childhood. Clin Dermatol 2012 Jan-Feb; 30: 114–127.

    Article  PubMed  Google Scholar 

  9. Swanson A, Canty K. Common pediatric skin conditions with protracted courses: a therapeutic update. Dermatol Clin 2013 Apr; 31: 239–249.

    Article  CAS  PubMed  Google Scholar 

  10. Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther 2007 Jul-Aug; 20: 229–238.

    Article  PubMed  Google Scholar 

  11. Falcini F, Capannini S, Martini G et al. Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus 2009 Feb; 18: 139–143.

    Article  CAS  PubMed  Google Scholar 

  12. Weatherhead SC, Wahie S, Reynolds NJ et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007 Feb; 156: 346–351.

    Article  CAS  PubMed  Google Scholar 

  13. Madan V, Griffiths CE. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther 2007 Jul-Aug; 20: 239–250.

    Article  CAS  PubMed  Google Scholar 

  14. Jauhola O, Ronkainen J, Autio-Harmainen H et al. Cyclosporine A vs. methylprednisolone for Henoch-Schonlein nephritis: a randomized trial. Pediatr Nephrol 2011 Dec; 26: 2159–2166.

    Article  PubMed  Google Scholar 

  15. Papandreou T, Durken M, Goebeler M et al. Chronic recalcitrant Henoch-Schonlein purpura: successful treatment with dapsone. Eur J Dermatol 2010 Sep-Oct; 20: 639–640.

    PubMed  Google Scholar 

  16. Ahrens F. Biologicals bei Atopischem Ekzem. Päd Allergo 2015; 18: 15–19.

    Google Scholar 

  17. Speth F, Wellinghausen N, Haas JP. Vorsorgeuntersuchungen während intensivierter Immunsuppression bei Kindern und Jugendlichen, Teil 1. Z Rheumatol 2013 Oct; 72: 814–821.

    Article  CAS  PubMed  Google Scholar 

  18. Ott H, Kopp M, Lange L. Kinderallergologie in Klinik und Praxis. Berlin [u.a.]: Springer Medizin, 2014, 2014.

  19. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000 May; 47: 63–83.

    Article  CAS  PubMed  Google Scholar 

  20. PfizerPharma. Fachinformation Methotrexat „Lederle“ Tabletten. Stand: Stand: Januar 2014. Zulassungsnummer 1974.00.01. Verfügbar unter: http://www.fachinfo.de/suche/fi/001333

  21. Deo M, Yung A, Hill S et al. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol 2014 Aug; 53: 1037–1041.

    Article  CAS  PubMed  Google Scholar 

  22. El-Khalawany MA, Hassan H, Shaaban D et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr 2013 Mar; 172: 351–356.

    Article  CAS  PubMed  Google Scholar 

  23. Höger PH. Kinderdermatologie: Differenzialdiagnostik und Therapie bei Kindern und Jugendlichen. Stuttgart: Schattauer, 2011, 2011.

  24. Dadlani C, Orlow SJ. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature. J Am Acad Dermatol 2005 Feb; 52: 316–340.

    Article  PubMed  Google Scholar 

  25. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S3-Leitlinie: Therapie der Psoriasis vulgaris. 23.02.2011. Verfügbar unter: http://www.awmf.org/uploads/tx_szleitlinien/013-001l_S3_Psoriasis_vulgaris_Therapie_01.pdf

  26. NovartisPharmaGmbH. Fachinformation Sandimmun 100mg/ml Lösung zum Einnehmen. Stand: September 2011

  27. Berth-Jones J, Finlay AY, Zaki I et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 1996 Jun; 34: 1016–1021.

    Article  CAS  PubMed  Google Scholar 

  28. Bunikowski R, Staab D, Kussebi F et al. Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects. Pediatr Allergy Immunol 2001 Aug; 12: 216–223.

    Article  CAS  PubMed  Google Scholar 

  29. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 2010 Dec; 63: 949–72; quiz 973.

    Article  CAS  PubMed  Google Scholar 

  30. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 Jul; 110: e2.

    Article  PubMed  Google Scholar 

  31. Keaney TC, Bhutani T, Sivanesan P et al. Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis. J Am Acad Dermatol 2012 Oct; 67: 636–641.

    Article  CAS  PubMed  Google Scholar 

  32. Ayer J, Young HS. Pimecrolimus for psoriasis. Expert Opin Pharmacother 2013 Apr; 14: 767–774.

    Article  CAS  PubMed  Google Scholar 

  33. Kazyra I, Pilkington C, Marks SD et al. Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child 2010 Dec; 95: 1059–1061.

    Article  PubMed  Google Scholar 

  34. Dagher R, Desjonqueres M, Duquesne A et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 2012 Mar; 32: 711–716.

    Article  PubMed  Google Scholar 

  35. Rouster-Stevens KA, Morgan GA, Wang D et al. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010 Oct; 62: 1446–1451.

    Article  Google Scholar 

  36. Epinette WW, Parker CM, Jones EL et al. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987 Dec; 17: 962–971.

    Article  CAS  PubMed  Google Scholar 

  37. Strathie Page SJ, Tait CP. Mycophenolic acid in dermatology a century after its discovery. Australas J Dermatol 2015 Feb; 56: 77–83.

    Article  PubMed  Google Scholar 

  38. Martini G, Ramanan AV, Falcini F et al. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford) 2009 Nov; 48: 1410–1413.

    Article  Google Scholar 

  39. Filler G, Hansen M, LeBlanc C et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 2003 May; 18: 445–449.

    Article  PubMed  Google Scholar 

  40. RochePharma. Fachinformation CellCept ® 1 g/5ml Pulver. Stand: Stand: Juli 2013. Zulassungsnummer EU/1/96/005/006. Verfügbar unter: HeumannPharma. Fachinformation Mycophenolatmofetil Heumann 250 mg Hartkapseln. Stand: 2/2014. Zulassungsnummer 80460.00.00. Verfügbar unter: http://www.fachinfo.de/suche/fi/012980

  41. Wolf R, Tuzun B, Tuzun Y. Dapsone: unapproved uses or indications. Clin Dermatol 2000 Jan-Feb; 18: 37–53.

    Article  CAS  PubMed  Google Scholar 

  42. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001 Sep; 45: 420–434.

    Article  CAS  PubMed  Google Scholar 

  43. Sardy M, Kasperkiewicz M. Bullöse Autoimmunerkrankungen bei Kindern. Hautarzt 2013 Jun; 64: 447–55; quiz 456.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kinder- und Jugendkrankenhaus AUF DER BULT, Janusz-Korczak-Allee 12, 30173, Hannover, Deutschland

    Antonia Reimer

Authors
  1. Antonia Reimer
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Danksagung

Die Autorin dankt Herrn PD Dr. Hagen Ott, Hannover, für die freundliche Bereitstellung der klinischen Abbildungen und die Durchsicht des Manuskriptes.

Interessenkonflikt

Die Autorin erklärt, dass bei der Erstellung des Beitrags kein Interessenkonflikt vorlag.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reimer, A. Systemische immunsuppressive Therapie in der Kinderdermatologie. Pädiatrie 27 (Suppl 7), 66–72 (2015). https://doi.org/10.1007/s15014-015-0464-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15014-015-0464-2

Search

Navigation